The Cancer AI Symposium positioning makes sense when you look at Tempus's data advantage with over 230,000 genomic tests and millions of clinical interactions. Their participation alongside Eli Lilly and Recursion shows how the real value is emerging from firms that combine data scale with clinical validation. The shift from diagnostics to real time clinical guidance is where Tempus could accelerate their monetizaton path beyond just testing.
The Cancer AI Symposium positioning makes sense when you look at Tempus's data advantage with over 230,000 genomic tests and millions of clinical interactions. Their participation alongside Eli Lilly and Recursion shows how the real value is emerging from firms that combine data scale with clinical validation. The shift from diagnostics to real time clinical guidance is where Tempus could accelerate their monetizaton path beyond just testing.